-
Mashup Score: 0
A novel anti-TIGIT antibody improved overall response rates and extended PFS when added to anti-PD-1 therapy and to anti-PD-1 therapy plus an adenosine receptor antagonist for patients with advanced, PD-L1-high non-small cell lung cancer.Results of the randomized phase 2 ARC-7 trial, presented during an ASCO Plenary Series session, showed tolerability of the agents, which exhibited similar safety
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Prior authorization has widespread negative impacts on cancer care, an ASCO survey of oncology providers showed.A majority of respondents indicated prior authorization requirements resulted in treatment delays, resulted in changes to treatment regimens and increased out-of-pocket costs. More than one-third of respondents reported prior authorization resulted in a patient death.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ASCO survey: Prior authorization leads to ‘indefensible delays’ in cancer care. https://t.co/dkug38Mzwy #HemOnc #OncAlert #MedEd #ASCOQLTY22 @ASCO #ASCOAdvocacy
-
-
Mashup Score: 0Building a New Normal: Symptom Self-Management Intervention May Benefit Cancer Survivors - The ASCO Post - 1 year(s) ago
An easy-to-deploy, automated self-management intervention may prove to be of benefit in supporting competence and symptom management among cancer survivors, according to data presented during the 2022 ASCO Quality Care Symposium.1 Analysis of the randomized controlled trial found that 12 months after enrollment, veterans who engaged with the intervention were more confident in their ability to…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Building a New Normal: Symptom Self-Management Intervention May Benefit Cancer Survivors https://t.co/1Sl233fVwn #ASCOQLTY22 #cancer #survivorship
-
-
Mashup Score: 1Outcomes of Immune Checkpoint Inhibitor Administration in Hospitalized Patients With Solid Tumor Malignancies - 1 year(s) ago
PURPOSE: More oncologists desire to treat their patients with immune checkpoint inhibitors (ICIs) in the inpatient setting as their use has become more widespread for numerous oncologic indications. This is cost-prohibitive to patients and institutions because of high drug cost and lack of reimbursement in the inpatient setting. We sought to examine current practice of inpatient ICI…
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet-
Important study that was presented at #ASCOQLTY22 👉🏻 Outcomes of Immune Checkpoint Inhibitor Administration in Hospitalized Patients With Solid Tumor Malignancies https://t.co/x9m5Ml6llK https://t.co/MZMpRkrxuT
-
-
Mashup Score: 1Multilayered Approach to Financial Toxicity Solutions for Patients With Cancer and Their Families - The ASCO Post - 1 year(s) ago
With out-of-pocket costs of cancer care exceeding $21 billion in 2019, financial toxicity among patients and their families in the United States has become too prevalent to ignore. In fact, more than 50% of working-age survivors now report at least one material, psychological, or behavioral domain of financial hardship. During the 2022 ASCO Quality Care Symposium, a panel of experts explored…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Multilayered Approach to Financial Toxicity Solutions for Patients With Cancer and Their Families https://t.co/PswFzcwVpG #cancer #costofcare #financialtoxicity #ASCOQLTY22
-
-
Mashup Score: 0
The pace of cancer drug development may have accelerated over the past decade, but so too has the cost of care, which threatens to limit access for a large percentage of Americans in the decade to come. During the keynote lecture at the 2022 ASCO Quality Care Symposium, Ezekiel J. Emanuel, MD, PhD, FASCO, BA, Vice Provost for Global Initiatives at the University of Pennsylvania, examined these…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Directions for Cancer Care: Major Trends in U.S. Health Policy https://t.co/Lf4bTsEst2 #cancer #oncology #healthcare #ASCOQLTY22
-
-
Mashup Score: 3Use of cannabis during cancer treatment may have ‘under-appreciated’ financial impact - 1 year(s) ago
Cannabis use during cancer treatment can result in a considerable out-of-pocket cost burden, according to study results presented at ASCO Quality Care Symposium.“This could be really underappreciated with our current tools for evaluating out-of-pocket costs and financial toxicity,” researcher Fumiko Chino, MD, radiation oncologist at Memorial Sloan Kettering Cancer Center, told
Source: www.healio.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to share our work evaluating the costs of #cannabis with @GoHealio @HemOncToday Our #ASCOQLTY22 study found that 1 in 5 patients surveyed used #cannabis during #cancer tx and the median cost was $80/mo. This may be an underappreciated expense. 💸🌿 https://t.co/xfM35yYBaU https://t.co/vQZBGpij5A
-
-
Mashup Score: 1Use of cannabis during cancer treatment may have ‘under-appreciated’ financial impact - 1 year(s) ago
Cannabis use during cancer treatment can result in a considerable out-of-pocket cost burden, according to study results presented at ASCO Quality Care Symposium.“This could be really underappreciated with our current tools for evaluating out-of-pocket costs and financial toxicity,” researcher Fumiko Chino, MD, radiation oncologist at Memorial Sloan Kettering Cancer Center, told
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Use of cannabis during cancer treatment may have ‘under-appreciated’ financial impact. https://t.co/4sYAP69sbb @fumikochino #cannabis #cancertreatment #symptommanagement #ASCOQLTY22 @ASCO #ASCOAdvocacy
-
-
Mashup Score: 1Xuesong Han on Medicaid Expansion and Receipt of Palliative Care Among Individuals Newly Diagnosed With Advanced-Stage Cancers - The ASCO Post - 2 year(s) ago
2022 ASCO Quality Care Symposium Xuesong Han, PhD, of the American Cancer Society, discusses findings showing that among newly diagnosed patients with stage IV cancers, Medicaid expansion was associated with increases in receipt of palliative care, although overall usage was low. The increase varied by cancer type. Improving Medicaid coverage may facilitate access to…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Xuesong Han, PhD, on Medicaid Expansion and Receipt of Palliative Care Among Individuals Newly Diagnosed With Advanced-Stage Cancers https://t.co/oe2x7PcIGk #ASCOQLTY22 #pallonc #Medicaid #oncology #cancer @AmericanCancer @HanXuesong @ACS_Research
-
-
Mashup Score: 0Samyukta Mullangi on Predictors of Compliance With Payer-Led Oncology Clinical Pathways - The ASCO Post - 2 year(s) ago
2022 ASCO Quality Care Symposium Samyukta Mullangi, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses her findings showing that physicians’ prescribing behavior may be influenced by payer-led pathways. Pathway compliance was associated with higher medical costs during a 6-month baseline period but lower health-care utilization, as measured in hospitalizations and…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Samyukta Mullangi, MD, MBA, on Predictors of Compliance With Payer-Led Oncology Clinical Pathways https://t.co/H6wuCZ7V8z #oncology #ASCOQLTY22 @SamyuktaMD @sloan_kettering
-
Anti-TIGIT regimens improve outcomes vs. anti-PD-1 alone in lung cancer subgroup. https://t.co/ebx2DvCEiC #HemOnc #OncAlert #MedEd #ASCOQLTY22 @ASCO #ASCOAdvocacy